R Kloner

Summary

Affiliation: Good Samaritan Hospital
Country: USA

Publications

  1. ncbi Effects of sildenafil on myocardial infarct size, microvascular function, and acute ischemic left ventricular dilation
    Thorsten Reffelmann
    The Heart Institute, Good Samaritan Hospital, University of Southern California, 1225 Wilshire Boulevard, Los Angeles, CA 90017-2395, USA
    Cardiovasc Res 59:441-9. 2003
  2. ncbi Cardiac uses of phosphodiesterase-5 inhibitors
    Bryan G Schwartz
    Heart Institute, Good Samaritan Hospital, 1225 Wilshire Boulevard, Los Angeles, CA 90017 2395, USA
    J Am Coll Cardiol 59:9-15. 2012
  3. ncbi Cardiovascular safety update of Tadalafil: retrospective analysis of data from placebo-controlled and open-label clinical trials of Tadalafil with as needed, three times-per-week or once-a-day dosing
    Robert A Kloner
    The Heart Institute, Good Samaritan Hospital, Cardiovascular Division, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
    Am J Cardiol 97:1778-84. 2006
  4. ncbi Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial
    Robert A Kloner
    Heart Institute, Good Samaritan Hospital, Cardiovascular Division of the Keck School of Medicine at University of Southern California, Los Angeles, CA 90017, USA
    Eur Heart J 27:2400-5. 2006
  5. ncbi Time course of the interaction between tadalafil and nitrates
    Robert A Kloner
    The Heart Institute, Good Samaritan Hospital, Cardiovascular Division, Keck School of Medicine, University of Southern California, Los Angeles, California 90017, USA
    J Am Coll Cardiol 42:1855-60. 2003
  6. ncbi Erectile dysfunction in the cardiac patient
    Robert A Kloner
    Heart Institute, Good Samaritan Hospital, 1225 Wilshire Boulevard, Los Angeles, CA 90017, USA
    Curr Urol Rep 4:466-71. 2003
  7. ncbi Efficacy of tadalafil in the treatment of erectile dysfunction in hypertensive men on concomitant thiazide diuretic therapy
    R A Kloner
    Division of Cardiovascular Medicine, Heart Institute, Good Samaritan Hospital, Keck School of Medicine at University of Southern California, Los Angeles, CA 90017, USA
    Int J Impot Res 17:450-4. 2005
  8. ncbi Roundtable discussion: tadalafil study group
    Robert A Kloner
    Division of Cardiovascular Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA
    Am J Cardiol 92:58M-65M. 2003
  9. ncbi Cardiovascular effects of tadalafil in patients on common antihypertensive therapies
    Robert A Kloner
    Division of Cardiovascular Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA
    Am J Cardiol 92:47M-57M. 2003
  10. ncbi Cardiovascular effects of tadalafil
    Robert A Kloner
    Division of Cardiovascular Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA
    Am J Cardiol 92:37M-46M. 2003

Research Grants

  1. Biologic Ventricular Assist Device
    Robert Kloner; Fiscal Year: 2004
  2. COLLABORATIVE R01-CARDIAC GRAFTS-FUNCTIONAL ANALYSES
    Robert Kloner; Fiscal Year: 2003
  3. Mesenchymal Stem Cells for Myocardial Infarction
    Robert Kloner; Fiscal Year: 2006

Detail Information

Publications89

  1. ncbi Effects of sildenafil on myocardial infarct size, microvascular function, and acute ischemic left ventricular dilation
    Thorsten Reffelmann
    The Heart Institute, Good Samaritan Hospital, University of Southern California, 1225 Wilshire Boulevard, Los Angeles, CA 90017-2395, USA
    Cardiovasc Res 59:441-9. 2003
    ..CONCLUSIONS: Sildenafil reduced cardiac pre- and afterload, and parameters of left ventricular contractility. Myocardial necrosis and microvascular dysfunction were neither exacerbated nor attenuated...
  2. ncbi Cardiac uses of phosphodiesterase-5 inhibitors
    Bryan G Schwartz
    Heart Institute, Good Samaritan Hospital, 1225 Wilshire Boulevard, Los Angeles, CA 90017 2395, USA
    J Am Coll Cardiol 59:9-15. 2012
    ..PDE5Is might also benefit patients with treatment-resistant hypertension, preeclampsia, or peripheral arterial disease. This review presents the pathophysiology and trial data with regard to the use of PDE5Is for cardiac diseases...
  3. ncbi Cardiovascular safety update of Tadalafil: retrospective analysis of data from placebo-controlled and open-label clinical trials of Tadalafil with as needed, three times-per-week or once-a-day dosing
    Robert A Kloner
    The Heart Institute, Good Samaritan Hospital, Cardiovascular Division, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
    Am J Cardiol 97:1778-84. 2006
    ..In this clinical trial population of men with erectile dysfunction, tadalafil was not associated with an increased risk for serious cardiovascular adverse events...
  4. ncbi Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial
    Robert A Kloner
    Heart Institute, Good Samaritan Hospital, Cardiovascular Division of the Keck School of Medicine at University of Southern California, Los Angeles, CA 90017, USA
    Eur Heart J 27:2400-5. 2006
    ..The purpose of this analysis was to determine whether the efficacy of adenosine vs. placebo was dependent on the timing of reperfusion therapy in the second Acute Myocardial Infarction Study of Adenosine (AMISTAD-II)...
  5. ncbi Time course of the interaction between tadalafil and nitrates
    Robert A Kloner
    The Heart Institute, Good Samaritan Hospital, Cardiovascular Division, Keck School of Medicine, University of Southern California, Los Angeles, California 90017, USA
    J Am Coll Cardiol 42:1855-60. 2003
    ..This study was designed to determine the time course of nitrate interaction with tadalafil, a phosphodiesterase 5 (PDE5) inhibitor with a half-life (t(1/2)) of 17.5 h...
  6. ncbi Erectile dysfunction in the cardiac patient
    Robert A Kloner
    Heart Institute, Good Samaritan Hospital, 1225 Wilshire Boulevard, Los Angeles, CA 90017, USA
    Curr Urol Rep 4:466-71. 2003
    ..These agents are mild vasodilators and are being investigated for their treatment potential for patients with pulmonary hypertension, heart failure, and endothelial dysfunction...
  7. ncbi Efficacy of tadalafil in the treatment of erectile dysfunction in hypertensive men on concomitant thiazide diuretic therapy
    R A Kloner
    Division of Cardiovascular Medicine, Heart Institute, Good Samaritan Hospital, Keck School of Medicine at University of Southern California, Los Angeles, CA 90017, USA
    Int J Impot Res 17:450-4. 2005
    ..More importantly, the responses to tadalafil were similar regardless of concomitant thiazide use. Additionally, responses to tadalafil were comparable between thiazide and nonthiazide users regardless of baseline ED severity (P>0.05)...
  8. ncbi Roundtable discussion: tadalafil study group
    Robert A Kloner
    Division of Cardiovascular Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA
    Am J Cardiol 92:58M-65M. 2003
  9. ncbi Cardiovascular effects of tadalafil in patients on common antihypertensive therapies
    Robert A Kloner
    Division of Cardiovascular Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA
    Am J Cardiol 92:47M-57M. 2003
    ..9%) who received placebo with concomitant antihypertensive agents. The data presented herein suggest that tadalafil is safe in patients receiving >or=1 concomitant antihypertensive agent...
  10. ncbi Cardiovascular effects of tadalafil
    Robert A Kloner
    Division of Cardiovascular Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA
    Am J Cardiol 92:37M-46M. 2003
    ..As with sildenafil, the use of tadalafil is contraindicated in patients receiving nitrate therapy because of the potential for significant hypotensive effects...
  11. ncbi Moving preconditioning from bench to bedside
    Robert A Kloner
    Heart Institute, Good Samaritan Hospital, Division of Cardiovascular Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California 90017, USA
    J Am Coll Cardiol 48:215-6. 2006
  12. ncbi Glycoprotein IIb/IIIa inhibitors and no-reflow
    Robert A Kloner
    Heart Institute, Good Samaritan Hospital, Los Angeles, California 90017, USA
    J Am Coll Cardiol 43:284-6. 2004
  13. ncbi Preconditioning, postconditioning and their application to clinical cardiology
    Robert A Kloner
    Heart Institute, Good Samaritan Hospital, Division of Cardiovascular Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90017, United States
    Cardiovasc Res 70:297-307. 2006
    ....
  14. ncbi Postconditioning markedly attenuates ventricular arrhythmias after ischemia-reperfusion
    Robert A Kloner
    Heart Institute, Good Samaritan Hospital and Division of Cardiovascular Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90017, USA
    J Cardiovasc Pharmacol Ther 11:55-63. 2006
    ..The purpose of this study was to determine if postconditioning limited reperfusion arrhythmias in a necrosis-free model...
  15. ncbi Erectile dysfunction and cardiovascular risk factors
    Robert A Kloner
    Heart Institute, Good Samaritan Hospital, Los Angeles, CA 90017, USA
    Urol Clin North Am 32:397-402, v. 2005
    ..Some have estimated that nearly one half of all causes of ED in men over 50 years of age are vascular in nature. This article reviews cardiovascular risk factors of ED...
  16. ncbi Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men
    Robert A Kloner
    The Heart Institute, Good Samaritan Hospital, Division of Cardiovascular Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California 90017, USA
    J Urol 172:1935-40. 2004
    ..We examined the hemodynamic interactions of tadalafil with the alpha-blockers doxazosin and tamsulosin...
  17. ncbi Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction
    Robert A Kloner
    Heart Institute, Good Samaritan Hospital, and the Division of Cardiovascular Medicine, Keck School of Medicine, University of Southern California, Los Angeles 90017, USA
    Circulation 110:3149-55. 2004
  18. ncbi Cardiac protection during acute myocardial infarction: where do we stand in 2004?
    Robert A Kloner
    Heart Institute, Good Samaritan Hospital, Division of Cardiovascular Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
    J Am Coll Cardiol 44:276-86. 2004
    ..Future studies powered to better assess clinical outcome are needed for adjunctive therapy with adenosine, K(ATP) channel openers, Na(+)/H(+) exchange inhibitors, and hypothermia...
  19. ncbi Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions
    Robert A Kloner
    Heart Institute, Good Samaritan Hospital, Keck School of Medicine, University of Southern California, Los Angeles, CA 90017, USA
    Am J Cardiol 96:42M-46M. 2005
    ..In contrast, recent studies have shown that PDE5 inhibitors may have therapeutic potential for a host of cardiovascular diseases. In general, these agents, when used appropriately, are highly safe and effective...
  20. ncbi A case of erectile dysfunction and risk factors for coronary artery disease
    R A Kloner
    Heart Institute, Good Samaritan Hospital and Division of Cardiovascular Medicine, Keck School of Medicine at the University of Southern California, Los Angeles, 90017, USA
    Int J Impot Res 17:S7-S11. 2005
    ..Methods to optimize efficacy of the phosphodiesterase inhibitors are described. The overall cardiovascular safety of the phosphodiesterase inhibitors and their interaction with organic nitrates and alpha blockers are discussed...
  21. ncbi Assessment of cardiovascular risk in patients with erectile dysfunction: focus on the diabetic patient
    Robert A Kloner
    Heart Institute, Good Samaritan Hospital, and Cardiovascular Division, Keck School of Medicine at University of Southern California, Los Angeles, CA 90017, USA
    Endocrine 23:125-9. 2004
    ..Studies to date have suggested that PDE5 inhibitors per se do not cause an increase in myocardial infarction rates in men being treated for ED...
  22. ncbi Novel phosphodiesterase type 5 inhibitors: assessing hemodynamic effects and safety parameters
    Robert A Kloner
    Division of Cardiovascular Medicine, Keck School of Medicine of the University of Southern California, Heart Institute, Good Samaritan Hospital, Los Angeles, California 90017, USA
    Clin Cardiol 27:I20-5. 2004
    ..Sildenafil has an alpha-blocker precaution; tadalafil is contraindicated with alpha blockers except for 0.4 mg tamsulosin; vardenafil is contraindicated with alpha blockers...
  23. ncbi Natural and unnatural triggers of myocardial infarction
    Robert A Kloner
    Heart Institute, Good Samaritan Hospital, Los Angeles, CA 90017, USA
    Prog Cardiovasc Dis 48:285-300. 2006
    ..Data regarding an increase in cardiac events during the 9/11 terrorist attack have been mixed. Understanding the cause of cardiovascular triggers will help in developing potential therapies...
  24. ncbi Erectile dysfunction and hypertension
    R Kloner
    Heart Institute, Good Samaritan Hospital USC, Los Angeles, CA, USA
    Int J Impot Res 19:296-302. 2007
    ..Organic nitrates remain an absolute contraindication for PDE5 inhibitors because synergistic and symptomatic reductions in BP may occur in some patients with this drug combination...
  25. ncbi Glucose-insulin-potassium for acute myocardial infarction: continuing controversy over cardioprotection
    Robert A Kloner
    Heart Institute, Good Samaritan Hospital, 1225 Wilshire Blvd, Los Angeles, CA 90017, USA
    Circulation 117:2523-33. 2008
  26. ncbi Comparison of acute myocardial infarct size in patients > or =65 years versus < 65 years in the prethrombolytic period versus the thrombolytic period
    Robert A Kloner
    Heart Institute, Good Samaritan Hospital, University of Southern California, Los Angeles, Los Angeles, California 90017, USA
    Am J Cardiol 89:1291-3. 2002
  27. ncbi Role of age, sex, and race on cardiac and total mortality associated with Super Bowl wins and losses
    Robert A Kloner
    Heart Institute, Good Samaritan Hospital, 1225 Wilshire Boulevard, Los Angeles, CA 90017, USA
    Clin Cardiol 34:102-7. 2011
    ..Total and cardiac mortality rates in Los Angeles County, California, increased after the 1980 Super Bowl loss (SBL), but there was an overall reduction in total mortality after the 1984 Super Bowl win (SBW)...
  28. ncbi Investigational noncardiovascular uses of phosphodiesterase-5 inhibitors
    Robert A Kloner
    The Heart Institute, Good Samaritan Hospital, 1225 Wilshire Blvd, Los Angeles, CA 90017 2395, USA
    Expert Opin Pharmacother 12:2297-313. 2011
    ....
  29. ncbi No-reflow phenomenon: maintaining vascular integrity
    Robert A Kloner
    Heart Institute, Good Samaritan Hospital, Keck School of Medicine, University of Southern California, Los Angeles, CA 90017, USA
    J Cardiovasc Pharmacol Ther 16:244-50. 2011
    ....
  30. ncbi Consequences of brief ischemia: stunning, preconditioning, and their clinical implications: part 2
    R A Kloner
    Heart Institute, Good Samaritan Hospital, Keck School of Medicine, University of Southern California, Los Angeles, USA
    Circulation 104:3158-67. 2001
    ..The future challenge is how to minimize the stunning phenomenon and maximize the preconditioning phenomenon in clinical practice...
  31. ncbi Consequences of brief ischemia: stunning, preconditioning, and their clinical implications: part 1
    R A Kloner
    Heart Institute, Good Samaritan Hospital, Keck School of Medicine, University of Southern California, Los Angeles, CA 90017, USA
    Circulation 104:2981-9. 2001
    ..The future challenge is how to minimize the stunning phenomenon and maximize the preconditioning phenomenon in clinical practice...
  32. ncbi Evidence for stunned myocardium in humans: a 2001 update
    R A Kloner
    Heart Institute, Good Samaritan Hospital, Los Angeles, California 90017, USA
    Coron Artery Dis 12:349-56. 2001
    ..Left atrial stunning following cardioversion is a recently recognized phenomenon with important clinical implications, but differs from the original concept of post-ischemic stunning...
  33. ncbi Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators
    R A Kloner
    The Heart Institute, Good Samaritan Hospital, University of Southern California, Los Angeles 90017 2308, USA
    Am J Cardiol 87:727-31. 2001
    ..Candesartan cilexetil offers a significant tolerability advantage with respect to less risk of developing peripheral edema...
  34. ncbi Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Sildenafil Study Group
    R A Kloner
    Heart Institute, Good Samaritan Hospital, and Department of Medicine, University of Southern California, Los Angeles 90017 2395, USA
    Am J Hypertens 14:70-3. 2001
    ..Sildenafil is an effective and well-tolerated treatment for ED in patients taking concomitant antihypertensive medication, including those on multidrug regimens...
  35. ncbi First direct comparison of the late sodium current blocker ranolazine to established antiarrhythmic agents in an ischemia/reperfusion model
    Robert A Kloner
    The Heart Institute, Good Samaritan Hospital, Los Angeles, CA 90017, USA
    J Cardiovasc Pharmacol Ther 16:192-6. 2011
    ..5 mg/kg, 2.5 mg/kg/hr infusion), ranolazine (IV bolus 3.3 mg/kg, 3.2 mg/kg per hour infusion), or saline (control)...
  36. ncbi Erectile dysfunction in patients with coronary artery disease
    R Kloner
    Heart Institute, Good Samaritan Hospital USC, Los Angeles, CA 90017, USA
    Int J Impot Res 17:209-15. 2005
    ..The Princeton Consensus Guidelines (soon to be updated) suggest a logical approach to the patient with CAD seeking therapy for sexual dysfunction...
  37. ncbi Uncertainty on the use of aldosterone antagonists for primary therapy for sudden cardiac death in the setting of implanted devices
    Robert A Kloner
    Heart Institute, Good Samaritan Hospital, 1225 Wilshire Blvd, Los Angeles, CA 90017, USA
    Circulation 115:2983-9; discussion 2989. 2007
  38. ncbi To drink or not to drink? That is the question
    Robert A Kloner
    Heart Institute, Good Samaritan Hospital, 1225 Wilshire Blvd, Los Angeles, CA 90017, USA
    Circulation 116:1306-17. 2007
    ..Perhaps the time has come for a prospectively randomized trial to determine whether 1 drink per day (or perhaps 1 drink every other day) reduces mortality and major cardiovascular events...
  39. ncbi Erectile dysfunction in the cardiac patient: how common and should we treat?
    Robert A Kloner
    Heart Institute, Good Samaritan Hospital, 1225 Wilshire Blvd, Los Angeles, California 90017, USA
    J Urol 170:S46-50; discussion S50. 2003
    ..However, most cardiologists do not routinely ask about ED and patients often are reluctant or embarrassed to discuss it. We determined how common ED was in a group of patients with chronic stable coronary artery disease...
  40. ncbi Erectile dysfunction as a predictor of cardiovascular disease
    R A Kloner
    Heart Institute, Good Samaritan Hospital, Los Angeles, CA 90017, USA
    Int J Impot Res 20:460-5. 2008
    ..If cardiovascular risk factors are identified, they should be worked up and aggressively treated--as treatment of these risk factors may be life-saving...
  41. ncbi Blood pressure control with amlodipine add-on therapy in patients with hypertension and diabetes: results of the Amlodipine Diabetic Hypertension Efficacy Response Evaluation Trial
    Robert A Kloner
    Heart Institute, Good Samaritan Hospital Professor of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90017, USA
    Ann Pharmacother 42:1552-62. 2008
    ..While therapeutic guidelines advise initial therapy with an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, monotherapy with these agents may not be sufficient to attain target BP...
  42. ncbi Comparison of total and cardiovascular death rates in the same city during a losing versus winning super bowl championship
    Robert A Kloner
    Heart Institute, Good Samaritan Hospital, Los Angeles, California, USA
    Am J Cardiol 103:1647-50. 2009
    ..3205 for control days, p = 0.0302). In conclusion, the emotional stress of loss and/or the intensity of a game played by a sports team in a highly publicized rivalry such as the Super Bowl can trigger total and cardiovascular deaths...
  43. ncbi Erectile dysfunction and atherosclerosis
    Robert A Kloner
    Heart Institute, Good Samaritan Hospital, 1225 Wilshire Boulevard, Los Angeles, CA 90017, USA
    Curr Atheroscler Rep 4:397-401. 2002
    ..Endothelial dysfunction and atherosclerosis of blood vessels that supply the penis are associated with the same cardiovascular risk factors that affect the coronary arteries: smoking, lipid abnormalities, hypertension, and diabetes...
  44. ncbi The antianginal agent ranolazine is a potent antiarrhythmic agent that reduces ventricular arrhythmias: through a mechanism favoring inhibition of late sodium channel
    Robert A Kloner
    The Heart Institute, Good Samaritan Hospital, Los Angeles, CA 90017, USA
    Cardiovasc Ther 29:e36-41. 2011
    ..Previously, we have shown that R suppresses ventricular arrhythmias at a concentration >10 μM that may affect multiple ion currents including IKr...
  45. ncbi Population-based analysis of the effect of the Northridge Earthquake on cardiac death in Los Angeles County, California
    R A Kloner
    Heart Institute, Good Samaritan Hospital, University of Southern California, Los Angeles 90017, USA
    J Am Coll Cardiol 30:1174-80. 1997
    ..We sought to determine whether a natural disaster affected total cardiovascular mortality and coronary mortality in an entire population...
  46. ncbi Postconditioning does not reduce myocardial infarct size in an in vivo regional ischemia rodent model
    Joan Dow
    The Heart Institute, Good Samaritan Hospital, and Division of Cardiovascular Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California 90017, USA
    J Cardiovasc Pharmacol Ther 12:153-63. 2007
    ..Postconditioning did not reduce myocardial infarct size with any of these regimens...
  47. ncbi Sexual function in hypertensive patients receiving treatment
    Thorsten Reffelmann
    University of Southern California, The Heart Institute, Good Samaritan Hospital, Division of Cardiovascular Medicine, Keck School of Medicine, Los Angeles, CA 90017-2395, USA
    Vasc Health Risk Manag 2:447-55. 2006
    ..Also, a-adrenoceptor blockers, such as doxazosin, terazosin and tamsulosin, should only be combined with phosphodiesterase 5 inhibitors with special caution and close monitoring of blood pressure...
  48. ncbi Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease
    Thorsten Reffelmann
    The Heart Institute, Good Samaritan Hospital, Division of Cardiovascular Medicine, University of Southern California, Los Angeles, CA 90017-2395, USA
    Circulation 108:239-44. 2003
  49. ncbi Postconditioning fails to improve no reflow or alter infarct size in an open-chest rabbit model of myocardial ischemia-reperfusion
    Sharon L Hale
    Heart Institute, Good Samaritan Hospital, 1225 Wilshire Boulevard, Los Angeles, CA 90017, USA
    Am J Physiol Heart Circ Physiol 294:H421-5. 2008
    ..PoC did not reduce infarct size in this model, nor did it reduce the extent of the anatomic zone of no reflow, suggesting that this intervention may not impact postreperfusion microvascular damage due to ischemia...
  50. ncbi Pharmacotherapy of erectile dysfunction: focus on cardiovascular safety
    Thorsten Reffelmann
    The Heart Institute, Good Samaritan Hospital, Division of Cardiovascular Medicine, Keck School of Medicine, University of Southern California, 1225 Wilshire Boulevard, Los Angeles, CA 90017-2395, USA
    Expert Opin Drug Saf 4:531-40. 2005
    ..When a stable cardiac condition can be achieved (low risk group), oral treatment for erectile dysfunction may be appropriate...
  51. ncbi Relationship between no reflow and infarct size as influenced by the duration of ischemia and reperfusion
    Thorsten Reffelmann
    The Heart Institute, Good Samaritan Hospital, University of Southern California, Los Angeles, California 90017-2395, USA
    Am J Physiol Heart Circ Physiol 282:H766-72. 2002
    ..Thus microvascular reperfusion injury led to a striking decrease in RMBF within the first 2 h of reperfusion, with infarct size as the major determinant of reflow at a given time point of reperfusion...
  52. ncbi Hypothermia during reperfusion limits 'no-reflow' injury in a rabbit model of acute myocardial infarction
    Sharon L Hale
    The Heart Institute of Good Samaritan Hospital, Los Angeles, CA 90017, USA
    Cardiovasc Res 59:715-22. 2003
    ..This study tests the effects of regional hypothermia, initiated late during ischemia and maintained for 2 h of reperfusion, on the no-reflow phenomenon...
  53. ncbi The gap junction uncoupler heptanol abrogates infarct size reduction with preconditioning in mouse hearts
    Guohu Li
    Heart Institute/Research, Good Samaritan Hospital and Section of Cardiology, Department of Medicine, University of Southern California, 1225 Wilshire Boulevard, Los Angeles, CA 90017-2395, USA
    Cardiovasc Pathol 11:158-65. 2002
    ....
  54. ncbi Ranolazine, an inhibitor of the late sodium channel current, reduces postischemic myocardial dysfunction in the rabbit
    Sharon L Hale
    Heart Institute of Good Samaritan Hospital and the Keck School of Medicine, Division of Cardiovascular Medicine, University of Southern California, Los Angeles 90017, USA
    J Cardiovasc Pharmacol Ther 11:249-55. 2006
    ..Ranolazine treatment reduced myocardial stunning following brief ischemia/reperfusion suggesting that inhibiting the late sodium channel current may be a novel approach to treating stunning independent of effects on hemodynamics...
  55. ncbi Late sodium current inhibition as a new cardioprotective approach
    Sharon L Hale
    The Heart Institute of Good Samaritan Hospital, Los Angeles, CA 90017, USA
    J Mol Cell Cardiol 44:954-67. 2008
    ..This article reviews published data describing the role of late sodium current and its inhibition by ranolazine in clinical and experimental studies of myocardial ischemia...
  56. ncbi A 4-year update on the safety of sildenafil citrate (Viagra)
    Harin Padma-Nathan
    The Male Clinic, Keck School of Medicine at the University of Southern California School of Medicine, Beverly Hills, California, USA
    Urology 60:67-90. 2002
    ..Lastly, we review the specific effects on the visual system based on findings from studies conducted during drug development and post marketing...
  57. ncbi The antianginal agent, ranolazine, reduces myocardial infarct size but does not alter anatomic no-reflow or regional myocardial blood flow in ischemia/reperfusion in the rabbit
    Sharon L Hale
    Good Samaritan Hospital, Los Angeles, California 90017, USA
    J Cardiovasc Pharmacol Ther 13:226-32. 2008
    ....
  58. ncbi Cardioprotective effects of angiotensin II type 1 receptor blockade with olmesartan on reperfusion injury in a rat myocardial ischemia-reperfusion model
    Wangde Dai
    The Heart Institute of Good Samaritan Hospital, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
    Cardiovasc Ther 28:30-7. 2010
    ..3 +/- 1.6% (P= 0.0018). Olmesartan significantly reduced myocardial infarct size and improved LV contractility at a dose (3 mg/kg) with systemic vasodilating effects but not at a lower dose (0.3 mg/kg) without hemodynamic effects...
  59. ncbi Survival and development of neonatal rat cardiomyocytes transplanted into adult myocardium
    Jochen Müller-Ehmsen
    Institute for Genetic Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    J Mol Cell Cardiol 34:107-16. 2002
    ..Those cells that did survive underwent differentiation and developed visible sarcomeres, suggesting a potential contribution toward ventricular function...
  60. ncbi Elevated body temperature during myocardial ischemia/reperfusion exacerbates necrosis and worsens no-reflow
    Sharon L Hale
    Heart Institute of Good Samaritan Hospital and Department of Medicine, University of Southern California, Los Angeles, California 90017, USA
    Coron Artery Dis 13:177-81. 2002
    ..The effects of an elevated body temperature on infarct size were tested in a rabbit model of ischemia/reperfusion...
  61. ncbi Cardioprotection with adenosine-regulating agent, GP531: effects on no-reflow, infarct size, and blood flow following ischemia/ reperfusion in the rabbit
    Sharon L Hale
    The Heart Institute of Good Samaritan Hospital, Los Angeles, CA 90017, USA
    J Cardiovasc Pharmacol Ther 15:60-7. 2010
    ....
  62. ncbi Acetaminophen and experimental acute myocardial infarction
    Sharon L Hale
    The Heart Institute of Good Samaritan Hospital, and the University of Southern California, Department of Medicine, Division of Cardiovascular Medicine, Los Angeles, CA 90017, USA
    Cardiovasc Drugs Ther 18:121-5. 2004
    ..We conclude that acetaminophen has a neutral effect in this experimental model of ischemia/reperfusion and appears to be safe in the course of experimental myocardial infarction...
  63. ncbi The "no-reflow" phenomenon: basic science and clinical correlates
    Thorsten Reffelmann
    The Heart Institute, Good Samaritan Hospital, University of Southern California, 1225 Wilshire Boulevard, Los Angeles, CA 90017-2395, USA
    Heart 87:162-8. 2002
  64. ncbi Cellular cardiomyoplasty--cardiomyocytes, skeletal myoblasts, or stem cells for regenerating myocardium and treatment of heart failure?
    Thorsten Reffelmann
    The Heart Institute, Good Samaritan Hospital, Cardiovascular Division, University of Southern California, 1225 Wilshire Boulevard, 90017 2395, Los Angeles, CA, USA
    Cardiovasc Res 58:358-68. 2003
  65. ncbi Ischemic preconditioning: a plea for rationally targeted clinical trials
    Robert A Kloner
    Heart Institute, Good Samaritan Hospital, 1225 Wilshire Boulevard, Los Angeles, CA 90017, USA
    Cardiovasc Res 55:526-33. 2002
  66. ncbi Direct and acute cardiotoxicity of ultrafine particles in young adult and old rat hearts
    Boris Z Simkhovich
    The Heart Institute, Good Samaritan Hospital, 1225 Wilshire Boulevard, Los Angeles, CA 90017, USA
    Basic Res Cardiol 102:467-75. 2007
    ..However the degree to which air pollutants affect cardiac responses in old hearts vs. their young adult counterparts has not been systematically addressed...
  67. ncbi Microvascular reperfusion injury: rapid expansion of anatomic no reflow during reperfusion in the rabbit
    Thorsten Reffelmann
    The Heart Institute, Good Samaritan Hospital, University of Southern California, Los Angeles, California 90017-2395, USA
    Am J Physiol Heart Circ Physiol 283:H1099-107. 2002
    ..06 +/- 0.01 ml x min(-1) x g(-1)). The development of macroscopic hemorrhage lagged behind no reflow, was closely correlated with it, and may be the consequence of microvascular damage...
  68. ncbi Is microvascular protection by cariporide and ischemic preconditioning causally linked to myocardial salvage?
    Thorsten Reffelmann
    Heart Institute, Good Samaritan Hospital, and Cardiovascular Division, University of Southern California, Los Angeles, California 90017 2395, USA
    Am J Physiol Heart Circ Physiol 284:H1134-41. 2003
    ..Because size and spatial distribution of no reflow and myocardial necrosis remained closely coupled with independent cardioprotective interventions, a potential causal connection between microvascular and myocardial salvage is discussed...
  69. ncbi Myocardial regeneration by embryonic stem cell transplantation: present and future trends
    Wangde Dai
    The Heart Institute, Good Samaritan Hospital, Division of Cardiovascular Medicine of the Keck School of Medicine at University of Southern California, Los Angeles, CA 90017 2395, USA
    Expert Rev Cardiovasc Ther 4:375-83. 2006
    ..However, there are still many hurdles to be overcome for the clinical application of embryonic stem cells...
  70. ncbi Direct and acute cardiotoxic effects of ultrafine air pollutants in spontaneously hypertensive rats and Wistar--Kyoto rats
    Hyosook Hwang
    Good Samaritan Hospital, Los Angeles, CA 90017, USA
    J Cardiovasc Pharmacol Ther 13:189-98. 2008
    ..7% in SHR versus WKY ( P < .05). The results of this study suggest that although UFP depress myocardial contractile response and coronary flow in both SHR and WKY the underlying hypertension does not necessarily worsen the response...
  71. ncbi Effects of acetaminophen on myocardial infarct size in rats
    Wangde Dai
    The Heart Institute, Good Samaritan Hospital, Division of Cardiovascular Medicine, University of Southern California, Los Angeles, Calif 90017, USA
    J Cardiovasc Pharmacol Ther 8:277-84. 2003
    ..CONCLUSION: Acetaminophen had no beneficial or adverse effects on infarct size in nonpreconditioned rats, and the beneficial effects of preconditioning were not blocked or prevented by acetaminophen at this analgesic dose...
  72. ncbi The no-reflow phenomenon: A basic mechanism of myocardial ischemia and reperfusion
    Thorsten Reffelmann
    The Heart Institute, Good Samaritan Hospital, Dept. of Cardiology, Division of Cardiovascular Medicine at Keck School of Medicine, University of Southern California, 1225 Wilshire Boulevard, Los Angeles (CA) 90017, USA
    Basic Res Cardiol 101:359-72. 2006
    ....
  73. ncbi Age-related changes of cardiac gene expression following myocardial ischemia/reperfusion
    Boris Z Simkhovich
    Heart Institute, Good Samaritan Hospital, Department of Medicine and Division of Cardiovascular Medicine, University of Southern California, Keck School of Medicine, Los Angeles, CA 90017, USA
    Arch Biochem Biophys 420:268-78. 2003
    ..These injury-related changes in gene expression could in part explain increased gravity of outcomes of ischemia and myocardial infarction in elderly hearts...
  74. ncbi No-reflow phenomenon persists long-term after ischemia/reperfusion in the rat and predicts infarct expansion
    Thorsten Reffelmann
    The Heart Institute, Good Samaritan Hospital, University of Southern California, 1225 Wilshire Blvd, Los Angeles, CA 90017, USA
    Circulation 108:2911-7. 2003
    ....
  75. ncbi Effects of adenosine and verapamil on anatomic no-reflow in a rabbit model of coronary artery occlusion and reperfusion
    Thorsten Reffelmann
    The Heart Institute, Good Samaritan Hospital, University of Southern California, Los Angeles, CA 90017-2395, USA
    J Cardiovasc Pharmacol 43:580-8. 2004
    ....
  76. ncbi Administration of erythropoietin fails to improve long-term healing or cardiac function after myocardial infarction in the rat
    Sharon L Hale
    The Heart Institute of Good Samaritan Hospital and the Keck School of Medicine, Division of Cardiovascular Medicine, University of Southern California, Los Angeles, California 90017, USA
    J Cardiovasc Pharmacol 46:211-5. 2005
    ..Thus, in our model, treatment with epo had no long-term beneficial effect on LV remodeling after myocardial infarction but may have exerted some positive effect on LV function...
  77. ncbi Erectile dysfunction in the cardiac patient
    Robert A Kloner
    Heart Institute, Good Samaritan Hospital, Division of Cardiovascular Medicine, Keck School of Medicine, University of Southern California, Los Angeles, Calif, USA
    Compr Ther 30:50-4. 2004
    ..Risk factors include: diabetes, lipid abnormalities, smoking, hypertension, obesity, and lack of physical activity. Oral phosphodiesterase-5 inhibitors appear effective and safe in most cardiac patients...
  78. ncbi Introduction: Erectile dysfunction and cardiovascular risk factors
    Robert A Kloner
    Division of Cardiovascular Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA
    Am J Cardiol 92:1-2. 2003
  79. ncbi Mesenchymal stem cell administration at coronary artery reperfusion in the rat by two delivery routes: a quantitative assessment
    Sharon L Hale
    The Heart Institute of Good Samaritan Hospital, Los Angeles, CA 90017, United States
    Life Sci 83:511-5. 2008
    ..However, MSC may not remain in the heart, but instead relocate to other areas. We investigated quantitatively the distribution of labeled rat MSC, given by two routes after coronary artery occlusion/reperfusion in rats...
  80. ncbi Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference)
    John B Kostis
    University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick, NJ, USA
    Am J Cardiol 96:313-21. 2005
    ..Finally, further research on the role of PDE-5 inhibition in treating patients with other medical or cardiovascular disorders is recommended...
  81. ncbi A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II)
    Allan M Ross
    Department of Medicine, George Washington University, Washington, DC, USA
    J Am Coll Cardiol 45:1775-80. 2005
    ..A larger study limited to the 70-microg/kg/min dose is, therefore, warranted...
  82. ncbi Vardenafil: a selective inhibitor of phosphodiesterase-5 for the treatment of erectile dysfunction
    Thorsten Reffelmann
    Klinik und Poliklinik für Innere Medizin B Ernst Moritz Arndt Universität Greifswald, Greifswald, Germany
    Expert Opin Pharmacother 8:965-74. 2007
    ..Importantly, any drug serving as a nitric oxide donor is contraindicated in combination with vardenafil...
  83. ncbi The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine
    Graham Jackson
    Cardiothoracic Center, St Thomas Hospital, London, UK
    J Sex Med 3:28-36; discussion 36. 2006
    ..The first Princeton Consensus Conference (Princeton I) in 1999 developed guidelines for safe management of cardiac patients regarding sexual activity and the treatment of ED...
  84. ncbi Update on clinical trials of tadalafil demonstrates no increased risk of cardiovascular adverse events
    Graham Jackson
    Guy s and St Thomas Hospital, London, UK
    J Sex Med 1:161-7. 2004
    ..Cardiovascular disease and erectile dysfunction (ED) share similar risk factors and often occur concomitantly. Therefore, men with ED may be at increased risk for cardiovascular adverse events...
  85. ncbi The "Merry Christmas Coronary" and "Happy New Year Heart Attack" phenomenon
    Robert A Kloner
    Circulation 110:3744-5. 2004
  86. ncbi Relationship between cyclooxygenase-2 inhibition and thrombogenesis
    Wangde Dai
    The Heart Institute, Good Samaritan Hospital, University of Southern California, 1225 Wilshire Boulevard, Los Angeles, CA 90017, USA
    J Cardiovasc Pharmacol Ther 9:51-9. 2004
    ..The roles of COX-2 in the pathophysiologic process of cardiovascular thrombosis are diverse and controversial, and need to be further studied to guide clinical practice...
  87. ncbi Molecular aspects of ischemic heart disease: ischemia/reperfusion-induced genetic changes and potential applications of gene and RNA interference therapy
    Margaret A Nordlie
    Division of Mathematics and Natural Sciences, University of Mary, Bismarck, ND, USA
    J Cardiovasc Pharmacol Ther 11:17-30. 2006
    ..Also discussed are future research directions, including the potential use of RNA interference and combined stem cell therapy and gene therapy for the treatment of cardiovascular disease...
  88. ncbi Sildenafil in patients with cardiovascular disease
    Ralph G Brindis
    Division of Cardiology, San Francisco Kaiser Hospital, San Francisco, California 94115, USA
    Am J Cardiol 92:26M-36M. 2003
    ..No association between sildenafil and increased cardiovascular morbidity or mortality has emerged in analyses of clinical trial data...
  89. ncbi Mechanisms of myocardial ischemic preconditioning are age related: PKC-epsilon does not play a requisite role in old rabbits
    Karin Przyklenk
    Department of Emergency Medicine, University of Massachusetts Medical School, Worcester, MA 01655, USA
    J Appl Physiol 95:2563-9. 2003
    ..brief PC ischemia was not associated with activation/translocation of PKC-epsilon. Thus the mechanisms responsible for PC are age related in the rabbit heart, with no apparent, requisite role of PKC-epsilon in aging animals...

Research Grants10

  1. Biologic Ventricular Assist Device
    Robert Kloner; Fiscal Year: 2004
    ..Identification and characterization of transplants will be carried out with PCR analysis of the Y chromosome (male cells into female host), detailed histologic analysis and immunostaining for muscle cell markers. ..
  2. COLLABORATIVE R01-CARDIAC GRAFTS-FUNCTIONAL ANALYSES
    Robert Kloner; Fiscal Year: 2003
    ....
  3. Mesenchymal Stem Cells for Myocardial Infarction
    Robert Kloner; Fiscal Year: 2006
    ..abstract_text> ..